Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anrotenib plus Toripalimab in Advanced Esophageal Squamous Cell Carcinoma
NCT04229849Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Jan 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of anlotinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Henan Cancer Hospital. Status: unknown.
02
Drugs
anlotinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04229849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04229849.